

HB 1875 -- ANTIPSYCHOTIC DRUGS

SPONSOR: Gregory

Currently, the MO HealthNet Division cannot impose any restrictions to access that preclude availability of any individual atypical antipsychotic monotherapy for the treatment of schizophrenia, bipolar disorder, or psychosis associated with severe depression. This bill prohibits any restrictions to access of any individual's antipsychotic medication.

The bill does not prohibit the division from utilizing clinical edits to ensure clinical best practices.

The division must issue a provider update no less than twice annually to enumerate treatment and utilization principles for MO HealthNet providers. If the division implements any new policy or clinical edit for an antipsychotic drug, the division must continue to allow MO HealthNet participants access to any antipsychotic drug that they are either using and on which they are stable or any drug that they have successfully used previously. The division may recommend a resource list with no restrictions to access of antipsychotic drugs.

This bill repeals requirements on the division as specified in the bill.

This bill is similar to HB 867 (2019).